Green Cross’s Hunter syndrome treatment approved in Korea

Published: 2012-01-17 06:56:00

Updated: 2012-01-17 06:56:00

Korea's leading vaccine manufacturer Green Cross Corp. has achieved a major success in its product development: The Korea Food and Drug Administration on Jan. 9 granted marketing approval for Hunterase

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK